<DOC>
	<DOCNO>NCT00381238</DOCNO>
	<brief_summary>This open-label extension study 49653/461 , assess long-term safety rosiglitazone ( extended release tablet ) subject mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Male female subject successfully complete 12 Month Visit 49653/461 ( 12 month treatment ) without tolerability issue , opinion subject investigator , beneficial continue treatment RSG XR . Female subject must postmenopausal ( i.e . &gt; 6 month without menstrual period ) , surgically sterile , childbearing potential , use effective contraceptive measure ( oral contraceptive , Norplant , DepoProvera , intrauterine device ( IUD ) diaphragm spermicide condom spermicide ) . Women childbearing potential must use effective contraceptive measure throughout study 30 day discontinue study medication . The subject caregiver must ensure subject continuously use contraceptive measure throughout duration study . Subject willing participate extension study provide full write informed consent prior performance protocolspecified procedure ; unable provide inform consent due cognitive status , full write informed consent behalf subject provide legally acceptable representative [ 1 ] . [ 1 ] Where accordance local law , regulation ethic committee policy . Caregiver provide full write informed consent behalf prior performance protocolspecified procedure . Exclusion criterion : Subject serious adverse experience ( SAE ) clinically significant laboratory abnormality 49653/461 , opinion investigator could attributable study medication , ongoing end 49653/461 . The subject felt investigator unsuitable ( basis health , compliance , caregiver availability , reason ) inclusion study base entry criterion primary study , 49653/461 ( exclusive age criterion may applicable subject ) . The subject experience significant cardiovascular event 49653/461 ( e.g . intervention , percutaneous coronary intervention , vascular surgery , acute coronary syndrome [ non Qwave myocardial infarction , Qwave myocardial infarction , unstable angina ] significant arrhythmia ) , unless thorough cardiovascular evaluation perform confirms subject congestive heart failure , clinically stable . Treatment cholinesterase inhibitor , selegiline , memantine treatment cognitive symptoms/AD initiate end 49653/461 .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Rosiglitazone</keyword>
</DOC>